Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q1
Sell
-85,400
Closed -$1.81M 7911
2019
Q4
$1.81M Buy
85,400
+60,400
+242% +$1.34M ﹤0.01% 3658
2019
Q3
$574K Buy
+25,000
New +$570K ﹤0.01% 4448
2018
Q4
Sell
-4,800
Closed -$189K 7990
2018
Q3
$189K Buy
+4,800
New +$216K ﹤0.01% 5109
2017
Q4
Sell
-18,500
Closed -$1.55M 7812
2017
Q3
$1.55M Buy
+18,500
New +$1.31M ﹤0.01% 3341
2017
Q1
Sell
-4,200
Closed -$246K 7590
2016
Q4
$246K Buy
+4,200
New +$222K ﹤0.01% 4649

Other funds holding ADNT

UBS Group's ADNT Position: Q1 2026 in Review

UBS Group increased its Adient (ADNT) stake by 4.2% in Q1 2026, buying an estimated $1.73M and bringing the position to 1,926,609 shares worth $38.9M. The position accounts for 0.01% of the portfolio, ranked #1892.

UBS Group first reported a position in ADNT in Q4 2016 and has held it in 38 quarters since. The position peaked at $77.2M in Q1 2018. 287 funds tracked by Wall St. Rank hold ADNT as of Q1 2026.

  • UBS Group held 1,926,609 shares of Adient worth $38.9M as of Q1 2026.
  • UBS Group bought 77,919 Adient shares in Q1 2026, an estimated $1.73M.
  • Adient made up 0.01% of UBS Group's portfolio in Q1 2026, its #1892 holding.
  • UBS Group first reported a position in Adient in Q4 2016 and has held it in 38 quarters since.
  • UBS Group's Adient position peaked at $77.2M in Q1 2018.
  • 287 funds tracked by Wall St. Rank held Adient as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.